Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma

Dual Faces of IFN  in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity

(2016) M. Mandai et al.   CLINICAL CANCER RESEARCH

Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan

(2016) Takamichi Ito et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study

(2014) Y. Fujisawa et al.   BRITISH JOURNAL OF DERMATOLOGY

Cutaneous Angiosarcoma: A Single-Institution Experience

(2013) Matthew C. Perez et al.   ANNALS OF SURGICAL ONCOLOGY

PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction

(2013) K. Abiko et al.   CLINICAL CANCER RESEARCH

CD8+tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma

(2013) Hiroko Fujii et al.   INTERNATIONAL JOURNAL OF CANCER

Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment

(2013) Daichi Hoshina et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival

(2013) E. J. Lipson et al.   Cancer Immunology Research

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

(2012) C. Badoual et al.   CANCER RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Postirradiation Primary Vaginal Angiosarcoma With Widespread Intra-abdominal Metastasis

(2011) Aidan Brady et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

Cutaneous angiosarcoma: own experience over 13 years. Clinical features, disease course and immunohistochemical profile

(2010) D Donghi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma

(2010) Mei-Chi Hsu et al.   MODERN PATHOLOGY

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival

(2009) Simone Muenst et al.   HUMAN PATHOLOGY

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

(2009) Dong-Ming Kuang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

(2008) Nicolas Penel et al.   JOURNAL OF CLINICAL ONCOLOGY